Volume 9, Issue 33 (12-2018)                   NCMBJ 2018, 9(33): 71-78 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Study of the effects of rs137852595 single-nucleotide polymorphism on drug resistance of androgen receptor against Enzalutamide treatments in patients with prostate. NCMBJ 2018; 9 (33) :71-78
URL: http://ncmbjpiau.ir/article-1-1159-en.html
Abstract:   (3615 Views)
Aim and Background:The aim of this study is to determine the role of rs137852595 single-nucleotide polymorphism in the resistance of androgen receptor against Enzalutamide treatments in patients suffer from prostate cancer.
Material and methods:In this paper, we performed the ARMS-PCR analysis on androgen receptor coding gene in 50 patients with prostate cancer with drug resistance and 50 patients with prostate cancer without drug resistance. Blood samples were gathered from patients admitted to Omid and al-Zahra hospitals of Isfahan province.
Results:The C and T allele frequencies in rs137852595 were 0.70 and 0.30 for drug resistant and 0.92 and 0.08 for control groups. In addition, investigation of gene heterozygosity revealed that the marker was in Hardy-Weinberg equilibrium.
Conclusion: The findings showed that there is a meaningful relationship between drug resistance and rs137852595 single-nucleotide polymorphism existence (P-Value = 0.005). Furthermore, results from studying of the drug resistance mechanism using the docking technique indicated that in patients with rs137852595 single-nucleotide polymorphism, the drug is not accurately bonded to the active site of androgen receptor, and binding energy of drug to the receptor is reduced.
 
Full-Text [PDF 528 kb]   (1095 Downloads)    
Type of Study: Research Article | Subject: Cellular and molecular
Received: 2018/12/17 | Accepted: 2018/12/17 | Published: 2018/12/17

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | New Cellular and Molecular Biotechnology Journal

Designed & Developed by : Yektaweb